Copyright © Inderes 2011 - present. All rights reserved.
  • Senaste
  • Börs
    • Aktiejämförelse
    • Börskalender
    • Utdelningskalender
    • Aktieanalys
    • Artiklar
  • InderesTV
  • Portfölj
  • Forum
  • Q&A
  • Om oss
    • Bolag under bevakning
    • Teamet
Regulatoriskt pressmeddelande

Revenio Group Corporation’s Annual Reporting package 2022 has been published

Revenio Group
Ladda ner börsmeddelandet

Revenio Group Corporation, Stock Exchange Release, March 1, 2023 at 10.00 a.m. (EET)

Revenio Group Corporation’s Annual Reporting package 2022 has been published

Revenio Group Corporation has published its annual reporting package for 2022. The annual reporting package comprises of Review by the Board of Directors, Financial Statements and Auditor’s Report, Sustainability Report, Corporate Governance Statement and Remuneration Report.

The reports are attached to this release and are also available to read and download in Finnish and English on the company’s website as separate pdf files:

www.reveniogroup.fi/fi/sijoittajat/raportit_ja_esitykset (in Finnish)

www.reveniogroup.fi/en/investors/reports_and_presentations (in English)

Revenio’s Financial Statements in accordance with European Single Electronic Format (ESEF) reporting requirements are published in Finnish and English. In line with the ESEF requirements, the primary statements and notes to the financial statements have been labelled with XBRL tags. The audit firm Deloitte Oy has provided an independent auditor’s reasonable assurance report on Revenio’s ESEF financial statements.

Revenio Group Corporation
Board of Directors

For further information, please contact
CFO Robin Pulkkinen, tel. +358 50 505 9932
robin.pulkkinen@revenio.fi

Distribution
Nasdaq Helsinki Ltd
Main media
www.revenio.fi

Revenio Group in brief
Revenio is a leading company in the global market for ophthalmological devices and software solutions. Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand. iCare is a trusted partner in ophthalmic diagnostics, offering physicians fast, easy-to-use, and reliable tools for the diagnosis of glaucoma, diabetic retinopathy, and macular degeneration (AMD). iCare Solutions provide digital clinical tools that drive greater efficiency and enhance quality in eye care.

In 2022, the Group’s net sales totaled EUR 97.0 million, with an operating profit of EUR 29.7 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Attachments


Revenio Group Corporation Report By The Board Of Directors And Financial Statements 2022
Revenio Group Corporation Remuneration Report 2022
Revenio Group Corporation Corporate Governance Statement 2022
Revenio Group Corporation Sustainability And ESG Report 2022
Reveniogroup 2022 12 31 En

Följ oss på våra kanaler i social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Ta kontakt
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • Om oss
  • Teamet
  • Jobba hos oss
  • Inderes som en investering
  • Tjänster för börsbolag
Vår plattform
  • FAQ
  • Servicevillkor
  • Integritetspolicy
  • Disclaimer
Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.